bimekizumab
bimekizumab is listed in the FDA National Drug Code directory with 6 NDC codes, marketed under brand name including Bimzelx. Available dosage forms: injection, solution, liquid.
Drug Details
- Generic Name
- bimekizumab
- Brand Names
- Bimzelx
- Application Number
- BLA761151
- Sponsor
- UCB, Inc.
- NDC Codes
- 6
- Dosage Forms
- INJECTION, SOLUTION, LIQUID
- Routes
- SUBCUTANEOUS
- Active Ingredients
- BIMEKIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) 1.1 Plaque Psoriasis BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis BIMZELX is indicated for the treatment of adults with active psoriatic arthritis. 1.3 Non-Radiographic Axial Spondyloarthritis BIMZELX is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. 1.4 Ankylosing Spondylitis BIMZELX is indicated for the treatment of adults with active ankylosing spondylitis. 1.5 Hidradenitis Suppurativa BIMZELX is indicated for the treatment of adults with moderate to severe hidradenitis suppurativa.